Mesenchymal Stromal Cells from Patients with Cyanotic Congenital Heart Disease are Optimal Candidate for Cardiac Tissue Engineering.
Bone marrow mesenchymal stromal cells
Cardiac patch
Cyanotic congenital heart disease
Hypoxia
Seeding cells
Tissue engineering
Journal
Biomaterials
ISSN: 1878-5905
Titre abrégé: Biomaterials
Pays: Netherlands
ID NLM: 8100316
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
30
03
2019
revised:
12
09
2019
accepted:
18
10
2019
pubmed:
26
11
2019
medline:
1
5
2021
entrez:
26
11
2019
Statut:
ppublish
Résumé
Engineered heart tissues (EHTs) are regarded as being the most promising alternative to synthetic materials, and autologous mesenchymal stem cells (MSCs) are widely used as seeding cells. However, few studies have evaluated the feasibility of using MSCs from patients with cyanotic congenital heart disease (C-CHD) as seeding cells for EHTs, in comparison with cells from patients of acyanotic congenital heart disease (A-CHD). In the present study, we cultured MSCs from A-CHD and C-CHD patients in normoxia or hypoxia conditions, and compared their pro-angiogenic, anti-apoptotic and inflammation-modulatory potentials. In vivo, we seeded the cells into collagen patches conjugated with, or without, proangiogenic cytokines, which were used to repair the right ventricular outflow tract (RVOT) of rats. The in vitro results showed that C-CHD MSCs expressed higher levels of VEGFA and VEGFR
Identifiants
pubmed: 31761487
pii: S0142-9612(19)30673-8
doi: 10.1016/j.biomaterials.2019.119574
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
119574Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.